Patient Death Triggers FDA Hold For Cellectis’s “Off the Shelf” CAR-T – Xconomy
Xconomy |
Patient Death Triggers FDA Hold For Cellectis's “Off the Shelf” CAR–T
Xconomy The FDA has forced Cellectis to shut down two Phase 1 trials it has been running to test an “off the shelf” type of cell therapy—a stinging setback to the France- and New York-based company's aspirations to leapfrog other developers of CAR–T, a type … FDA hits Cellectis' off-the-shelf CAR–T program with clinical hold after first patient treated in phase 1 trial dies In staggering setback, toxic reaction kills Cellectis' first CAR–T patient, forcing trial halt Cellectis Reports Clinical Hold of UCART123 Studies |
